Harmony Biosciences Holdings Inc (HRMY)
29.02
-0.29
(-0.99%)
USD |
NASDAQ |
May 17, 16:00
29.02
0.00 (0.00%)
After-Hours: 20:00
Harmony Biosciences Holdings Revenue (Quarterly): 154.62M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 154.62M |
| December 31, 2023 | 168.41M |
| September 30, 2023 | 160.27M |
| June 30, 2023 | 134.22M |
| March 31, 2023 | 119.13M |
| December 31, 2022 | 128.31M |
| September 30, 2022 | 117.21M |
| June 30, 2022 | 107.03M |
| March 31, 2022 | 85.31M |
| Date | Value |
|---|---|
| December 31, 2021 | 91.21M |
| September 30, 2021 | 80.73M |
| June 30, 2021 | 73.82M |
| March 31, 2021 | 59.67M |
| December 31, 2020 | 56.29M |
| September 30, 2020 | 45.61M |
| June 30, 2020 | 38.00M |
| March 31, 2020 | 19.84M |
| December 31, 2019 | 5.995M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
5.995M
Minimum
Dec 2019
168.41M
Maximum
Dec 2023
91.43M
Average
88.26M
Median
Revenue (Quarterly) Benchmarks
| Amylyx Pharmaceuticals Inc | 88.64M |
| Exelixis Inc | 425.23M |
| Insmed Inc | 75.50M |
| Ultragenyx Pharmaceutical Inc | 108.83M |
| Immunic Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 38.33M |
| Total Expenses (Quarterly) | 102.58M |
| EPS Diluted (Quarterly) | 0.67 |
| Enterprise Value | 1.466B |
| Gross Profit Margin (Quarterly) | 82.22% |
| Profit Margin (Quarterly) | 24.79% |
| Earnings Yield | 7.96% |
| Operating Earnings Yield | 11.80% |
| Normalized Earnings Yield | 8.369 |